Vycor Medical Reports Q1 Profitability & Positive Cash Flow Amidst Going Concern Doubt
VYCO has more than doubled off its 52-week low of $0.032.
Summary
Vycor Medical reported a return to profitability and positive cash flow from operations in Q1 2026, a major improvement for the micro-cap company, but it still faces a near-term debt maturity and ongoing going concern doubts.
Key Events · Earnings and Guidance · VYCO
-
Operational Turnaround to Profitability
The company achieved net income of $20,108 in Q1 2026, a significant improvement from a net loss of $(38,563) in Q1 2025.
-
Positive Cash Flow from Operations
Cash provided by operating activities was $99,422 in Q1 2026, a substantial reversal from cash used in operations of $(26,909) in Q1 2025.
-
Persistent Going Concern Doubt
Management continues to express substantial doubt about the company's ability to continue as a going concern, citing accumulated losses and a working capital deficiency of $4,297,001 as of March 31, 2026.
-
Critical Debt Maturity Approaching
A term note for $300,000 plus $580,866 in accrued interest to EuroAmerican Investment Corp. is due on June 30, 2026, with no assurance of further extension or sufficient cash to meet the obligation.
Analysis · VYCO · Industrial Applications And Services
Vycor Medical's Q1 2026 results show a significant operational turnaround, moving from a net loss and negative cash flow from operations in the prior year to profitability and positive cash flow. This is a crucial development for a company that continues to report substantial doubt about its ability to continue as a going concern. However, the company faces an immediate liquidity challenge with a significant debt obligation of $880,866 (principal and accrued interest) due to EuroAmerican Investment Corp. on June 30, 2026, for which it currently lacks sufficient cash. The ongoing material weakness in internal controls also remains a concern.
At the time of this filing, VYCO was trading at $0.07 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $0.03 to $0.50. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.